March 3 (Reuters) - Valeant Pharmaceuticals International
Inc , responding to investors' queries, said on
Thursday that Executive Vice President Deb Jorn had not been
asked to leave, reiterating that she had resigned for personal
reasons.

Jorn oversaw the Canadian drugmaker's U.S. dermatology
business, which had ties with Philidor Rx Services, a specialty
pharmacy that came under fire for using aggressive tactics to
increase insurer reimbursement, mostly for dermatology drugs.

Valeant in October severed its ties with Philidor, which has
since shut shop. The company's relationship with Philidor is the
focus of an investigation by the U.S. Securities and Exchange
Commission, Reuters reported.

A Valeant board committee is also investigating the
company's ties with Philidor, and the drugmaker on Thursday said
Jorn's departure "is not the result of an action taken by the Ad
Hoc Committee of the Board of Directors".
Continued...